Back to search results

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

SLE (Systemic Lupus) · Lupus Erythematosus, Systemic · Lupus Nephritis · Systemic Sclerosis · Inflammatory Myopathy, Idiopathic · Myositis · Diffuse Cutaneous Systemic Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Research Site 4, Redwood City, California, United States

  • Research Site 2, Chicago, Illinois, United States

  • Research Site 8, Iowa City, Iowa, United States

  • Research Site 14, New Orleans, Louisiana, United States

  • Research Site 6, Boston, Massachusetts, United States

  • Research Site 1, St Louis, Missouri, United States

  • Research Site 5, Chapel Hill, North Carolina, United States

  • Research Site 7, Augsburg, Germany

  • Research Site 13, Cologne, Germany

  • Research Site 3, Hanover, Germany

  • Research Site 12, Mainz, Germany

  • Research Site 10, Córdoba, Spain

  • Research Site 9, Pamplona, Spain

  • Research Site 11, Seville, Spain

View source on ClinicalTrials.gov(opens in a new tab)